Tivomax instructions

Posted on by admin

Tivomax-Darnitsa instructions

Tivomax-Darnitsa instructions for use

for medical purposes

Stock

active substance : arginine hydrochloride;

1 ml dose of arginine hydrochloride – 42 mg;

Table of contents:

additional water : water for injections.

Medicine form

Dispensing for infusions.

The main physical and chemical properties: the color is barless or slightly yellowish-brown.

Pharmacotherapeutic group

Hematopoiesis and perfusion disorders. Additional items for internal administration. Amino acids. Arginine hydrochloride. Code ATX B05X B01.

Pharmacological authorities

Arginine is an amino acid that belongs to the class of mentally essential and is an active and diverse cellular regulator of numerous vitally important functions of the body, and is important in critical situations for the body’s protective effect. ekti.

The drug exhibits antihypoxic, membrane stabilizing, cytoprotective, antioxidant, antiradical, detoxification activity, acts as an active regulator of intermediary metabolism and energy supply processes, plays an important role in maintaining hormonal balance in the body. It appears that arginine is more abundant in the blood than insulin, glucagon, somatotropic hormone and prolactin, and is involved in the synthesis of proline, polyamine, agmatine, and is involved in the process of fibrinolysis, spermatogenesis, and repair. membrane depolarizing action.

Arginine is one of the substrates in the cycle of amino acid synthesis in the liver. The hypomonimonic effect of the drug is realized through the activation of the transformation of ammonia into the substance. The hepatoprotective action is due to antioxidant, antihypoxic and membrane stabilizing activity, which positively influences the energy supply processes in hepatocytes.

The drug is a substrate for NO synthase, an enzyme that catalyzes the synthesis of nitric oxide in endotheliocytes. The drug activates guanylate cyclase and promotes the release of cyclic guanidine monophosphate in the endothelium of blood vessels, changes the activation and adhesion of leukocytes and platelets to the endothelium of blood vessels, suppresses the synthesis of proteins genesis of VCAM-1 and MCP-1, thus preventing the creation and development of atherosclerotic plaques, suppresses the synthesis of endothelin-1, which is a tightening vasoconstrictor and stimulator of proliferation and migration of smooth myocytes of the vessel wall. The drug also inhibits the synthesis of asymmetric dimethylarginine, a powerful endogenous stimulator of oxidative stress. The drug stimulates the thymus, which produces T-cells, and regulates blood glucose levels during physical activity. Carry out an acid-removing action and correct the acid-water flow.

With continuous internal infusion, the maximum concentration of arginine hydrochloride in the blood plasma is avoided through the injection site. The drug penetrates the placental barrier, is filtered in the glomeruli, but is practically completely reabsorbed in the glomeruli.

Clinical characteristics

Showing

Atherosclerosis of the vessels of the heart and brain; atherosclerosis of peripheral vessels, including with manifestations of intermittent vomiting. Diabetic angiopathy.

Ischemic heart disease. Angina pectoris. Become after suffering from acute myocardial infarction and acute damage to cerebral blood flow. Chronic heart failure.

Chronic obstructive illness. Interstitial pneumonia. Idiopathic pulmonary hypertension. Chronic post-embolic hypertension. Hypoxic conditions.

Acute and chronic hepatitis of various etiologies.

Asthenic conditions in the process of convalescence, including after infectious illness and surgical treatment.

Decreased function of the thymus.

Curing the development of the fetus. Preeclampsia.

Contraindicated

Increased sensitivity to the drug.

History of allergic reactions.

Severe impairment of function, hypochloremic acidosis.

Prescription of potassium-sparing diuretics, spironolactone.

Interactions with other medicinal drugs and other types of interactions

Potassium-sparing diuretics, spironolactone. When taking the drug, it is necessary to take care that it can cause severe hyperkalemia due to nicotine deficiency in patients who are taking or have taken spironolactone. Pre-administration of potassium-sparing diuretics may also reduce elevated potassium concentrations in the blood.

Aminophylline. With one-hour stagnation with aminophylline, there may be an increase in the level of insulin in the blood.

Arginine is not incompatible with thiopental.

In patients with nitric deficiency, it is necessary to check the diuresis and level of potassium in the blood plasma before starting the infusion, as the drug may cause the development of hyperkalemia.

The drug should be used with caution in case of impaired function of the endocrine glands. The drug can stimulate the secretion of insulin and growth hormone. If dry mouth appears, it is necessary to check the level of sugar in the blood.

The slide should be carefully frozen in case of disruption of the exchange of electrolytes or illness.

If symptoms of asthenia increase on aphids taking the drug, treatment must be administered.

Suspension during pregnancy or breastfeeding.

The drug penetrates the placenta, so during the period of gestation it can only stagnate if the extracted measles for the mother outweighs the potential sac for the fetus.

Consideration should be given to the use of the drug during the period of breastfeeding every day. During the bathing period, it is necessary to wash the chest.

This is due to the fluidity of the reaction during treatment with vehicles or other mechanisms.

The drug can cause contamination, so care must be taken when handling vehicles or working with other mechanisms.

Method of congestion and dosage

The drug is administered internally in drops at a rate of 10 drops per line, stretching the first lines, then the speed of administration can be increased to 30 drops per line.

The additional dose of the drug is 100 ml per dose.

In case of severe impairment of blood flow in the central and peripheral vessels, with signs of intoxication, hypoxia, asthenic conditions, the dose of the drug can be increased to 200 ml per dose.

The maximum fluidity of the infusion dose should not exceed 20 mmol/year.

For children under 12 years of age, the dose of the drug is 5-10 ml per 1 kg of body weight per dose.

The drug should be given to children over 3 years of age.

Overdose

Symptoms: nitric deficiency, hypoglycemia, metabolic acidosis.

Likuvannya. In case of overdose, the infusion of the drug must be injected. Next, monitor physiological reactions and support the vital functions of the body. If necessary, introduce necessary supplements and supplements to improve diuresis (saluretics), release of electrolytes (0.9% sodium chloride, 5% glucose).

Adverse reactions

Underworld disorders: hyperthermia, feeling hot, body aches.

Changes at the point of administration: hyperemia, itching, paleness of the skin, even to cyanosis.

On the side of the cystic-ulcerative system: pain in the nodules.

On the side of the herbal system: dry mouth, boredom, vomiting.

On the side of the immune system: hypersensitivity reactions, including hissing, weeping, angioedema.

On the side of the cardiovascular system: arterial tension, changes in heart rhythm, pain in the heart.

On the side of the nervous system: headache, confusion, fear, weakness, seizures, tremor - more often with excessive fluid administration.

Changes in laboratory findings: hyperkalemia.

Term of attribution

Umovi sberіgannya

Store in original packaging at a temperature not exceeding 25 °C. Do not freeze. Keep out of the reach of children.

Insanity

The drug is not crazy with thiopental.

100 ml per bottle; 1 bottle per pack; 100 ml bottles.

Release category

Virobnik

PrJSC "Pharmaceutical Firm "Darnitsa".

Locality of the distributor and address of the locality of promotion of activities

Ukraine, 02093, m. Kiev, st. Boryspilska, 13.

Source: http://medtab.com.ua/tivomaks-darnitsa/instrukciya/

Tivomax

Price: from 77.60 UAH Can be purchased in 2 pharmacies Rating:

About the drug:

Arginine is an amino acid that belongs to the class of conditionally essential and is an active and versatile cellular regulator of numerous vital functions of the body, exhibiting protective effects that are important in a critical condition of the body.

Indications and dosage:

Atherosclerosis of the vessels of the heart and brain, atherosclerosis of peripheral vessels, including manifestations of intermittent claudication

Cardiac ischemia

Conditions after acute myocardial infarction and acute cerebrovascular accident

Chronic heart failure

Chronic obstructive pulmonary diseases

Idiopathic pulmonary hypertension

Chronic post-embolic pulmonary hypertension

Acute and chronic hepatitis of various etiologies

Asthenic conditions during convalescence, including after infectious diseases and surgical interventions

Decreased thymus function

Fetal growth restriction

The drug is administered intravenously at a rate of 10 drops per minute for the first minutes, then the rate of administration can be increased to 30 drops per minute.

Daily dosage of solution.

In case of severe circulatory disorders in the central and peripheral vessels, with severe symptoms of intoxication, hypoxia, and asthenic conditions, the dose can be increased to 200 ml per day.

The maximum rate of administration of infusion solutions should not exceed 20 mmol/h.

For children under 12 years of age, the dose of the drug is 5-10 ml per 1 kg of body weight per day.

The drug is used for children aged 3 years and older.

Overdose:

Symptoms: renal failure, hypoglycemia, metabolic acidosis.

Treatment. In case of overdose, the drug infusion must be stopped. Physiological reactions and maintenance of vital functions of the body should be monitored. If necessary, administer medications and means for establishing diuresis (saluretics), electrolyte solutions (0.9% sodium chloride solution, 5% glucose solution).

Side effects:

General disorders: hyperthermia, feeling of heat, body aches.

Changes at the injection site: hyperemia, itching, pale skin, to cyanosis.

From the musculoskeletal system: joint pain.

From the digestive system: dry mouth, nausea, vomiting.

From the immune system: hypersensitivity reactions, including rash, urticaria, angioedema.

From the cardiovascular system: fluctuations in blood pressure, changes in heart rate, pain in the heart area.

From the nervous system: headache, dizziness, feeling of fear, weakness, convulsions, tremors - more often when the rate of administration is exceeded.

Changes in laboratory parameters: hyperkalemia.

Contraindications:

Hypersensitivity to the drug.

History of allergic reactions.

Severe renal dysfunction, hypochloremic acidosis.

The use of potassium-sparing diuretics, spironolactone.

The drug crosses the placenta, so during pregnancy it can be used only when the expected benefit to the mother outweighs the potential risk to the fetus.

There are no data on the use of the drug during breastfeeding. During the period of treatment it is necessary to stop breastfeeding.

Interaction with other drugs and alcohol:

Potassium-sparing diuretics, spironolactone. When using the drug, it is necessary to take into account that it can cause severe and persistent hyperkalemia against the background of renal failure in patients taking or have taken spironolactone. Pretreatment with potassium-sparing diuretics may also increase blood potassium concentrations.

Aminophylline. When used simultaneously with aminophylline, an increase in insulin levels in the blood is possible.

Arginine is incompatible with thiopental.

Composition and properties:

Active ingredient: arginine hydrochloride

1 ml arginine hydrochloride - 42 mg

Excipients: water for injection.

100 ml in a bottle; 1 bottle in a pack; 100 ml each.

The drug has antihypoxic, membrane stabilizing, cytoprotective, antioxidant, antiradical, detoxification activity, manifests itself as an active regulator of intermediate metabolism and energy supply processes, plays a certain role in maintaining hormonal balance in the body. It is known that arginine increases the blood levels of insulin, glucagon, growth hormone and prolactin, participates in the synthesis of proline, polyamine, agmatine, is involved in the processes of fibrinolysis, spermatogenesis, and has a membrane depolarizing effect.

Arginine is one of the substrates in the urea synthesis cycle in the liver. The hypoammonemic effect of the drug is realized by activating the conversion of ammonia to urea. It has a hepatoprotective effect due to antioxidant, antihypoxic and membrane-stabilizing activity, and has a positive effect on energy supply processes in hepatocytes.

The drug is a substrate for NO synthase, an enzyme that catalyzes the synthesis of nitric oxide in endothelial cells. The drug activates guanylate cyclase and increases the level of cyclic guanidine monophosphate in the vascular endothelium, reduces the activation and adhesion of leukocytes and platelets to the vascular endothelium, suppresses the synthesis of adhesion proteins VCAM-1 and MCP-1, thereby preventing the formation and development of atherosclerotic plaques, suppresses the synthesis of endothelin-1, which is a powerful vasoconstrictor and stimulator of proliferation and migration of smooth myocytes of the vascular wall. The drug also suppresses the synthesis of asymmetric dimethylarginine, a powerful endogenous stimulator of oxidative stress. The drug stimulates the thymus, which produces T cells, and regulates blood glucose levels during exercise. It has an acid-producing effect and helps correct acid-base balance.

Store in original packaging at a temperature not exceeding 25 ° C. Do not freeze. Keep out of the reach of children.

Algo-Farm

Login using:

Login using:

The information published on the site is for informational purposes only. Described methods of diagnosis, treatment, traditional medicine recipes, etc. It is not recommended to use it yourself. Be sure to consult a specialist so as not to harm your health!

Source: http://www.likar.info/lekarstva/Tivomaks/

LAVOMAX

◊ Tablets, yellow to orange, round; The core of the tablet is orange.

Excipients: magnesium hydroxycarbonate (heavy magnesium carbonate) - 69 mg, povidone Kmg, calcium stearate - 2 mg.

Shell composition: sucrose - 158.11 mg, povidone K17 - 5.65 mg, copovidone - 0.44 mg, magnesium hydroxycarbonate (light magnesium carbonate) - 25.7 mg, titanium dioxide - 1.2 mg, colloidal silicon dioxide (Aerosil A-380) - 1 mg, dye quinoline yellow - 0.09 mg, sunset yellow dye - 0.01 mg, macrogolmg, beeswax - 0.15 mg, liquid paraffin - 0.15 mg, talc - 1.5 mg.

3 pcs. — cellular contour packages (1) — cardboard packs.

3 pcs. — contour cell packaging (2) — cardboard packs.

4 things. — cellular contour packages (1) — cardboard packs.

4 things. — contour cell packaging (2) — cardboard packs.

6 pcs. — cellular contour packages (1) — cardboard packs.

6 pcs. — contour cell packaging (2) — cardboard packs.

10 pieces. — cellular contour packages (1) — cardboard packs.

10 pieces. — contour cell packaging (2) — cardboard packs.

Antiviral and immunomodulatory drug. Lavomax stimulates the formation of α-, β-, γ-interferons in the body. In response to Lavomax administration, interferon is produced mainly by intestinal epithelial cells, hepatocytes, T-lymphocytes and neutrophils.

After taking the drug orally, the maximum production of interferon is determined in the sequence intestine-liver-blood after 4-24 hours. Lavomax has an immunomodulatory and antiviral effect. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the T-helper/T-suppressor ratio.

Effective against various viral infections, incl. against influenza viruses, other acute respiratory viral infections, hepatitis and herpes viruses, cytomegaloviruses and neurotropic viruses.

The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which viral reproduction is suppressed.

After taking the drug orally, tilorone is quickly absorbed from the gastrointestinal tract. Bioavailability is 60%.

Binding to blood plasma proteins is about 80%.

Metabolism and excretion

Tiloron does not undergo biotransformation and does not accumulate in the body. It is excreted almost unchanged in feces (about 70%) and urine (about 9%). T 1/2 is 48 hours.

The drug is used in adults as part of complex therapy:

— infectious-allergic and viral encephalomyelitis;

- urogenital and respiratory chlamydia;

Treatment and prevention of influenza and other acute respiratory viral infections.

- lactation period (breastfeeding);

- children and adolescents up to 18 years of age;

- sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption (the drug contains sucrose);

- hypersensitivity to the components of the drug.

The drug is taken orally after meals.

When treating influenza and other acute respiratory viral infections - in the first two days of the disease - 125 mg, then - 125 mg every other day. Course dose of mg (per course of treatment - 6 tablets of 125 mg each).

For the prevention of influenza and other acute respiratory viral infections - 125 mg once a week for 6 weeks. For a course of treatment - 6 tablets. 125 mg each.

For the treatment of viral hepatitis A - the first day, 125 mg 2 times, then 125 mg every other day. The course dose is 1.25 g (per course of treatment - 10 tablets of 125 mg each).

For the treatment of acute hepatitis B - 125 mg on the first and second days, then 125 mg every other day. The course dose is 2 g (per course of treatment - 16 tablets of 125 mg each), for protracted hepatitis Vmg 2 times a day on the first day, then 125 mg every other day. The course dose is 2.5 g (per course of treatment - 20 tablets of 125 mg each).

For chronic hepatitis B - the initial phase of treatment (2.5 g) - the first two days, 250 mg, then 125 mg every other day. Continuation phase (from 1.25 g to 2.5 g) - 125 mg per week. The course dose of the drug Lavomax is from 3.75 to 5 g (per course of treatment - from 30 to 40 tablets of 125 mg), the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process.

For acute hepatitis C - 125 mg on the first and second days, then 125 mg every other day. The course dose is 2.5 g (per course of treatment - 20 tablets of 125 mg each).

For chronic hepatitis C - the initial phase of treatment (2.5 g) - the first two days, 250 mg, then every other day. Continuation phase (2.5 g) - 125 mg per week. The course dose of the drug Lavomax is 5 g (per course of treatment - 40 tablets of 125 mg each). The duration of therapy is 6 months, depending on the results of biochemical, immunological, and morphological markers of the activity of the process.

For the treatment of herpetic and cytomegalovirus infections - the first two days, 125 mg, then every other day, 125 mg. The course dose is 2.5 g (per course of treatment - 20 tablets of 125 mg each).

For urogenital and respiratory chlamydia, non-gonococcal urethritis - the first two days, 125 mg, then every other day, 125 mg. The course dose is 1.25 g (per course of treatment - 10 tablets of 125 mg each).

As part of complex therapy for pulmonary tuberculosis - 250 mg for the first two days, then 125 mg every other day. The course dose is 2.5 g (per course of treatment - 20 tablets of 125 mg each).

As part of complex therapy for neuroviral infections, the dose is set individually, the course of treatment is 4 weeks.

Possible: short-term chills, allergic reactions, symptoms of dyspepsia.

There are no known cases of overdose of Lavomax.

No clinically significant interaction of the drug Lavomax with antibiotics, standard therapy for viral and bacterial diseases, or alcohol has been identified.

Compatible with antibiotics and standard therapy for viral and bacterial diseases.

Impact on the ability to drive vehicles and operate machinery

The use of the drug does not affect the ability to drive vehicles or engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Contraindicated in children and adolescents under 18 years of age.

The drug should be stored out of the reach of children, in a dry, dark place at a temperature not exceeding 25°C. Shelf life: 2 years.

To ask a question about the project or contact the editors, use this form.

Source: http://health.mail.ru/drug/lavomax/

Lavomax

Description current as of 02/24/2016

  • Latin name: Lavomax
  • ATX code: L03AX
  • Active ingredient: Tilorone
  • Manufacturer: NIZHFARM (Russia)

Compound

Lavomax contains tilorone dihydrochloride as an active substance, and additional components: calcium stearate, magnesium hydroxycarbonate pentahydrate, povidone.

The shell consists of povidone, sucrose, copovidone, magnesium hydroxycarbonate pentahydrate, colloidal silicon dioxide, titanium dioxide, macrogol 6000, liquid paraffin, beeswax, talc, dye.

Release form

This medicine is produced in the form of yellow or orange coated tablets. The core is orange. The tablets are round. The contour package can contain 3, 4, 6 or 10 tablets.

pharmachologic effect

Lavomax tablets have an immunomodulatory and antiviral effect.

The active component stimulates the production of interferons in the body. After the administration of Lavomax, interferon is produced mainly by hepatocytes, intestinal epithelial cells, neutrophils, and T-lymphocytes.

After the antiviral drug Lavomax has been taken orally, the highest degree of interferon production occurs as follows: intestines-liver-blood. This process begins after 4-24 hours. Under its influence, brain stem cells are stimulated, antibodies are formed, and the degree of immunosuppression is reduced. There is also a restoration of the T-helper/T-suppressor ratio.

The mechanism of its influence is associated with the process of inhibiting the translation of virus-specific proteins in those cells that have been infected. As a result, viral reproduction is suppressed.

Pharmacokinetics and pharmacodynamics

After the drug has been taken orally, the substance tilorone is quickly absorbed from the digestive tract. Bioavailability is 60%. Approximately 80% binds to blood proteins.

The active component does not undergo biotransformation and does not accumulate in the body. Most of it is excreted unchanged in feces (approximately 70%), a small part is excreted in urine (approximately 9%). Half-life is 48 hours.

Indications for use

The instructions for the drug define the following indications for the use of Lavomax in adult patients:

Lavomax is used as part of complex treatment.

Contraindications

Before taking Lavomax, you should take into account the contraindications that are indicated in the instructions for the medicine. These are:

Side effects

While taking the pills, the following side effects may occur:

Lavomax tablets, instructions for use

According to the instructions for use of Lavomax, the tablets should be taken after meals.

Patients with influenza and ARVI are prescribed 125 mg of Lavomax in the first 2 days, then 125 mg every other day. A total dose of 750 mg is used throughout the course of treatment.

To prevent influenza and ARVI, you need to take 125 mg of Lavomax once a week for six weeks.

For the treatment of viral hepatitis A, 125 mg of the drug is prescribed twice a day, after which you need to take 125 mg of the drug every other day. The total dose per course is 1.25 g.

For the treatment of hepatitis B in acute form, a dose of 125 mg of drugs is prescribed in the first two days, then 125 mg every other day. The total dose per course is 2 g. If the disease is protracted, then the total dose per course is 2.5 g (that is, 20 tablets)

If a patient is diagnosed with chronic hepatitis B, he is prescribed 250 mg in the first 2 days, then 125 mg every other day. The total dose of Lavomax per course is 3.75-5 g. The duration of therapy can be up to 6 months. In this case, the doctor takes into account the results of laboratory tests that characterize the activity of the pathological process in the patient.

For hepatitis C, 125 mg of Lavomax is prescribed in the first 2 days, then 125 mg every other day. The total dose per course is 2.5 g. In the case of chronic hepatitis C, 250 mg is prescribed in the first two days, then 125 mg every other day. The total dose per course is 5 g. The duration of administration is determined by the doctor, taking into account laboratory parameters. Therapy can last up to 6 months.

When treating cytomegalovirus or herpetic infections, 125 mg of Lavomax is prescribed in the first 2 days, then in the same dose every other day. The total dose per course is 2.5 g. Treatment of genital herpes involves a similar dosage regimen.

Patients with non-gonococcal urethritis, respiratory and urogenital chlamydia are prescribed 125 mg in the first 2 days, then in the same dose every other day. The total dose per course is 1.25 g.

The complex treatment of pulmonary tuberculosis includes taking 250 mg of Lavomax in the first 2 days, then 125 mg every other day. The dose per course is 2.5 g.

In the complex treatment of neuroviral infections, the dosage is determined by the doctor on an individual basis. Treatment lasts 4 weeks.

Overdose

There have been no recorded cases of Lavomax overdose.

Interaction

No clinically significant interaction of Lavomax with other drugs, in particular antibiotics, has been determined, which is why the tablets can be taken together with antibacterial agents and other drugs that are used in the treatment of bacterial and viral diseases.

Terms of sale

Lavomax can be purchased without a prescription.

Storage conditions

Store at temperatures up to 25°C. It is necessary to protect the tablets from exposure to moisture and light, and keep them away from children.

Best before date

The shelf life of Lavomax tablets is 2 years.

special instructions

Does not affect the ability to drive vehicles or operate dangerous machinery.

Patients interested in whether Lavomax is an antibiotic or not should note that the drug has an exclusively antiviral effect.

Lavomax's analogues

Those who are interested in whether cheaper analogs of Lavomax are available for sale should know about the existence of drugs with a similar effect, such as Amiksin, Tiloron. These drugs are produced by Russian pharmaceutical companies, so their cost is lower.

Also, Actaviron, Tiloram and Tilaxin have a similar effect on the body.

Alcohol and Lavomax

Drinking alcohol during treatment is not recommended, since combining medication and ethanol can lead to the development of asthenia and a serious deterioration in well-being. The development of allergic manifestations is also possible. In addition, with this combination the effect on the functions of the immune system will be extremely negative.

For children

Lavomax is not prescribed to patients under 18 years of age.

During pregnancy and lactation

Treatment with Lavomax is contraindicated both during pregnancy and during breastfeeding.

Reviews of Lavomax

There are varied reviews about Lavomax on the forums. Many users write about the tablets as an effective means for preventing colds and flu. It is also noted that the tablets act in the treatment of viral diseases, allowing you to quickly get rid of unpleasant symptoms. Reviews from doctors about Lavomax indicate that the drug is more effective as part of a complex treatment.

Lavomax price, where to buy

How much the medicine costs depends on the packaging of the drug. The price of Lavomax tablets (6 pieces) ranges from 610 to 700 rubles. Packaging cost is 10 pcs. -rub.

The price of Lavomax in Ukraine (Nikolaev, Kharkov, etc.) is hryvnia per pack of 3 pcs. Buy medicine in a package of 10 pcs. in Odessa and other cities you can get it for a price starting from 370 hryvnia.

  • Online pharmacies in Russia Russia
  • Online pharmacies in Ukraine Ukraine
  • Online pharmacies in Kazakhstan Kazakhstan

WER.RU

ZdravZone

Pharmacy IFC

Pharmacy24

PaniPharmacy

BIOSPHERE

Education: Graduated from Rivne State Basic Medical College with a degree in Pharmacy. Graduated from Vinnitsa State Medical University named after. M.I. Pirogov and internship at his base.

Work experience: From 2003 to 2013 – worked as a pharmacist and manager of a pharmacy kiosk. She was awarded diplomas and decorations for many years of conscientious work. Articles on medical topics were published in local publications (newspapers) and on various Internet portals.

Inna: Usually, insomnia occurs for me due to some kind of experience and when you lie down, it’s not.

Olesya: I tried glycine forte, which is more expensive in the price category, but the dosage is the same.

Andrey: Not a word is said about choosing the size of stockings according to a person’s parameters: height, leg size, etc.

Olga: For coxarthrosis of the 2nd degree, I have been injecting for 4 years at the rate (after 6 months), there is no improvement.

All materials presented on the site are for reference and informational purposes only and cannot be considered a treatment method prescribed by a doctor or sufficient advice.

The site administration and the authors of the articles are not responsible for any losses and consequences that may arise when using the site materials.

Source: http://medside.ru/lavomaks

TIVOMAX-DARNITSA, Darnitsa

Name: TIVOMAX-DARNITSA, Darnitsa

Pharmacological properties

pharmacodynamics. Arginine is an amino acid that belongs to the class of conditionally essential and is an active and versatile cellular regulator of numerous vital functions of the body, and has protective effects that are important in a critical condition of the body.

The drug has antihypoxic, membrane stabilizing, cytoprotective, antioxidant, antiradical, detoxification effects, manifests itself as an active regulator of intermediate metabolism and energy supply processes, and plays a certain role in maintaining hormonal balance in the body. It is known that arginine increases the blood levels of insulin, glucagon, growth hormone and prolactin, takes part in the synthesis of proline, agmatine polyamine, is involved in the processes of fibrinogenolysis, spermatogenesis, and has a membrane depolarizing effect.

Arginine is one of the substrates in the urea synthesis cycle in the liver. The hypoammonemic effect of the drug is realized by activating the conversion of ammonia to urea. It has a hepatoprotective effect due to antioxidant, antihypoxic and membrane-stabilizing activity, and has a positive effect on energy supply processes in hepatocytes.

The drug is a substrate for NO synthase, an enzyme that catalyzes the synthesis of nitric oxide in endothelial cells. The drug activates guanylate cyclase and increases the level of cyclic guanidine monophosphate in the vascular endothelium, reduces the activation and adhesion of leukocytes and platelets to the vascular endothelium, inhibits the synthesis of adhesion proteins VCAM-1 and MCP-1, thus preventing the formation and development of atherosclerotic plaques, suppresses the synthesis of endothelin-1, which is a powerful vasoconstrictor and stimulator of proliferation and migration of smooth myocytes of the vascular wall. The drug also suppresses the synthesis of asymmetric dimethylarginine, a powerful endogenous stimulator of oxidative stress. The drug stimulates the thymus, which produces T cells, regulates blood glucose levels during exercise. It has an acid-forming effect and helps correct acid-base balance.

Pharmacokinetics. With continuous infusion, Cmax of arginine hydrochloride in blood plasma is achieved within 20–30 minutes from the start of administration. The drug penetrates the placental barrier, is filtered in the renal glomeruli, but is almost completely reabsorbed in the renal tubules.

Composition and release form

Other ingredients: water for injection.

No. UA/13827/01/01 from 09/03/2014 to 09/03/2019 By prescription

Indications

atherosclerosis of the vessels of the heart and brain, atherosclerosis of peripheral vessels, including manifestations of intermittent claudication. Diabetic angiopathy. IHD. Angina pectoris. Conditions after acute myocardial infarction and acute cerebrovascular accident. Chronic heart failure. AG. Hypercholesterolemia. COPD Interstitial pneumonia. Idiopathic pulmonary hypertension. Chronic post-embolic pulmonary hypertension. Hypoxic conditions. Acute and chronic hepatitis of various etiologies. Hyperammonemia. Asthenic conditions during the period of convalescence, including after infectious diseases and surgical interventions. Decreased function of the thymus gland. Delayed fetal development. Preeclampsia.

Application

the drug is administered intravenously at a rate of 10 drops per minute for the first 10–15 minutes, then the rate of administration can be increased to 30 drops per minute. The daily dose of the drug is 100 ml of solution.

In case of severe circulatory disorders in the central and peripheral vessels, with severe symptoms of intoxication, hypoxia, and asthenic conditions, the dose can be increased to 200 ml/day.

The maximum rate of administration of the infusion solution should not exceed 20 mmol/h.

For children under 12 years of age, the dose of the drug is 5–10 ml per 1 kg of body weight per day.

Contraindications

hypersensitivity to the drug. History of allergic reactions. Severe renal dysfunction, hypochloremic acidosis. The use of potassium-sparing diuretics, spironolactone.

Side effects

general disorders: hyperthermia, feeling of heat, body aches.

Changes at the injection site: hyperemia, itching, pale skin up to cyanosis.

From the musculoskeletal system: joint pain.

From the digestive system: dry mouth, nausea, vomiting.

From the immune system: hypersensitivity reactions, including rash, urticaria, angioedema.

From the cardiovascular system: fluctuations in blood pressure, changes in heart rate, pain in the heart area.

From the nervous system: headache, dizziness, fear, weakness, convulsions, tremors - more often when the rate of administration is exceeded.

Changes in laboratory parameters: hyperkalemia.

special instructions

in patients with renal failure, before starting the infusion, it is necessary to monitor diuresis and the level of potassium in the blood plasma, since the drug may contribute to the development of hyperkalemia.

The drug is used with caution in cases of dysfunction of the endocrine glands. The drug can stimulate the secretion of insulin and growth hormone. If you experience dry mouth, you need to monitor your blood glucose levels.

It should be used with caution in cases of electrolyte metabolism disorders and kidney diseases.

If the severity of symptoms of asthenia increases while taking the drug, treatment should be discontinued.

Use during pregnancy and lactation. The drug penetrates the placental barrier, so during pregnancy it can be used only when the expected benefit to the mother outweighs the potential risk to the fetus.

There are no data regarding the use of the drug during breastfeeding. During the period of treatment it is necessary to stop breastfeeding.

Children. The drug is used in children over 3 years of age.

The ability to influence reaction speed when driving vehicles or other mechanisms. The drug may cause dizziness, so care must be taken when driving or operating other machinery.

Interactions

potassium-sparing diuretics, spironolactone. When using the drug, it is necessary to take into account that it can cause severe and persistent hyperkalemia against the background of renal failure in patients taking or who have taken spironolactone. Pretreatment with potassium-sparing diuretics may also increase blood potassium concentrations.

Aminophylline. When used simultaneously with aminophylline, an increase in insulin levels in the blood is possible.

Arginine is incompatible with thiopental .

Incompatibility. The drug is incompatible with thiopental.

Overdose

symptoms: renal failure, hypoglycemia, metabolic acidosis.

Treatment. In case of overdose, the drug infusion must be stopped. Physiological reactions and maintenance of vital body functions should be monitored. If necessary, administer alkalizing agents and means for normalizing diuresis (saluretics), solutions of electrolytes (0.9% sodium chloride solution, 5% glucose solution).

Storage conditions

in original packaging at a temperature not exceeding 25 °C. Do not freeze.

ALPHABETIC INDEX

Medprep.info is a leading reference book for medications and diseases with detailed instructions and photos.

This material is for educational purposes only and is not intended for medical advice, diagnosis or treatment.

Source: http://medprep.info/drug/medicament/tivomaks-darnitsa-darnitsa

Lavomax - official instructions for use

on medical use of the drug

Registration number

Trade name of the drug

International nonproprietary name

Dosage form

film-coated tablets

Compound

One tablet contains:

core: active ingredient – ​​tilorone dihydrochloride – 125 mg; excipients: magnesium hydroxycarbonate (heavy magnesium carbonate) – 69 mg, povidone K30 – 4 mg, calcium stearate – 2 mg;

shell: sucrose – 158.11 mg, povidone K17 – 5.65 mg, copovidone – 0.44 mg, magnesium hydroxycarbonate (light magnesium carbonate) – 25.7 mg, titanium dioxide – 1.2 mg, colloidal silicon dioxide (aerosil A-380) 1 mg, quinoline yellow dye - 0.09 mg, sunset yellow dye 0.01 mg, macrogol-6000 - 6 mg, beeswax - 0.15 mg, liquid paraffin -0.15 mg, talc - 1.5 mg.

Film-coated tablets, yellow to orange in color, round in shape. The core of the tablet is orange.

Pharmacotherapeutic group

Antiviral immunostimulating agent – ​​inducer of interferon formation

Pharmacological properties

Tilorone stimulates the formation of alpha, beta, gamma and lambda interferons in the body. The main producers of interferon in response to the administration of tilorone are intestinal epithelial cells and hepatocytes. T lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence intestine - liver - blood after 4-24 hours.

Tiloron has an immunomodulatory and antiviral effect. Induces the synthesis of interferon in human leukocytes. Stimulates bone marrow stem cells, enhances antibody formation, reduces the degree of immunosuppression, restores the T-helper/T-suppressor ratio. Effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpes viruses.

The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which viral reproduction is suppressed.

After oral administration, Tilorone is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of tilorone is bound to plasma proteins. Tilorone is excreted almost unchanged through the intestines (70%) and through the kidneys (9%). The half-life is 48 hours. Tiloron does not undergo biotransformation and does not accumulate in the body.

Indications for use

— treatment and prevention of influenza and other acute respiratory viral infections;

- as part of complex therapy for herpes infection, cytomegalovirus infection;

- as part of complex therapy of urogenital and respiratory chlamydia. in complex therapy of non-gonococcal urethritis;

— as part of complex therapy for viral hepatitis A, B, C;

— as part of complex therapy of pulmonary tuberculosis;

- as part of complex therapy of infectious-allergic and viral encephalomyelitis.

Contraindications

Hypersensitivity to the drug.

Pregnancy and lactation period.

Children's age (up to 18 years).

Sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption (the drug contains sucrose).

Directions for use and doses

The drug is taken orally after meals.

When treating influenza and other acute respiratory viral infections - in the first two days of illness, 125 mg, then after 48 hours, 125 mg. The course dose is 750 mg (per course of treatment – ​​6 tablets of 125 mg each).

For the prevention of influenza and other acute respiratory viral infections - 125 mg once a week for 6 weeks (per course of treatment - 6 tablets of 125 mg).

For the treatment of herpetic cytomegalovirus infection - the first two days, 125 mg, then after 48 hours, 125 mg. The course dose is 1.25-2.5 g (per course of treatment – ​​125 mg tablets).

For urogenital and respiratory chlamydia, non-gonococcal urethritis - the first two days, 125 mg, then after 48 hours, 125 mg. The course dose is 1.25 g (per course of treatment - 10 tablets of 125 mg each).

For the treatment of viral hepatitis A - the first day, 125 mg 2 times, then 125 mg every 48 hours. The course dose is 1.25 g (per course of treatment - 10 tablets of 125 mg each).

For the treatment of acute hepatitis B - 125 mg on the first and second days, then 125 mg every 48 hours. The course dose is 2 g (per course of treatment - 16 tablets of 125 mg), for prolonged hepatitis B - 125 mg 2 times a day on the first day, then 125 mg after 48 hours. The course dose is 2.5 g (per course of treatment - 20 tablets of 125 mg each).

For chronic hepatitis B - the initial phase of treatment (2.5 g) - the first two days, 125 mg 2 times a day, then 125 mg after 48 hours. Continuation phase (from 1.25 g to 2.5 g) – 125 mg per week. The course dose of Lavomax ® is from 3.75 to 5 g (per course of treatment - from 30 to 40 tablets of 125 mg), duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process.

For acute hepatitis C - the first and second days, 125 mg, then 125 mg after 48 hours. The course dose is 2.5 g (per course of treatment - 20 tablets of 125 mg each).

For chronic hepatitis C - the initial phase of treatment (2.5 g) - the first two days, 125 mg 2 times a day, then 125 mg after 48 hours. Continuation phase (2.5 g) – 125 mg per week. The course dose of Lavomax ® is 5 g (per course of treatment - 40 tablets of 125 mg), duration of therapy - 6 months, depending on the results of biochemical, immunological, morphological markers of the activity of the process.

As part of complex therapy for pulmonary tuberculosis - 250 mg for the first two days, then 125 mg after 48 hours. The course dose is 2.5 g (per course of treatment - 20 tablets of 125 mg each).

As part of complex therapy for infectious-allergic and viral encephalomyelitis - pomg per day for the first 2 days of treatment, then 125 mg after 48 hours. The dose is set individually, the course of treatment is 3-4 weeks.

Side effect

Allergic reactions, dyspepsia, short-term chills are possible.

Overdose

There are no known cases of Lavomax ® overdose.

Interaction with other drugs

Compatible with antibiotics and standard therapy for viral and bacterial diseases.

No clinically significant interaction of Lavomax ® with antibiotics, standard therapy for viral and bacterial diseases, or alcohol has been identified.

Impact on the ability to drive vehicles and operate machinery

The use of the drug does not affect the ability to drive vehicles or engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Release form

Film-coated tablets, 125 mg.

3, 4, 6 or 10 tablets per blister pack. One or two blister packs along with instructions for use of the medicinal product are placed in a cardboard pack.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Best before date

2 years. Do not use the drug after the expiration date indicated on the package.

Conditions for dispensing from pharmacies

Manufacturer/organization accepting claims

JSC Nizhpharm, Russia

603950, Nizhny Novgorod, GSP-459, st. Salganskaya, 7

Source: http://medi.ru/instrukciya/lavomaks_2704/

Lavomax: instructions for use

The drug Lavomax is a stimulator of interferon production in the body and belongs to the group of antiviral immunomodulatory agents.

Release form and composition of the medicinal product

Lavomax is available in the form of tablets for oral use, coated with an orange or yellow protective coating. The drug is packaged in blisters of 3, 4, 6 or 10 pieces in a cardboard box, which also includes detailed instructions with a description.

The main active ingredient of the drug is Tilorone dihydrochloride, each tablet contains 125 mg of this component. In addition to the active substance, the drug contains chemical auxiliary components.

Pharmacological properties

Lavomax is an immunostimulating and antiviral agent. When the drug enters the gastrointestinal tract, Tiloron dihydrochloride is absorbed by the walls of the small intestine into the systemic bloodstream, after which the body begins to increase the production of interferons under the influence of this drug.

The maximum production of interferons while taking the drug is observed after 4 hours. Lavomax stimulates the work of bone marrow stem cells and enhances the formation of antibodies. The drug is highly effective against many pathogens of viral infections, including influenza viruses, parainfluenza, acute respiratory diseases, hepatitis viruses, cytomegalovirus, and herpetic infections.

The active ingredient of the drug penetrates directly into the cell damaged by the virus, blocking its reproduction at the DNA level.

Indications for use

The drug Lavomax is prescribed to patients as a primary, auxiliary or prophylactic agent for the following conditions:

  • Cytomegalovirus infection;
  • Herpetic rashes on the skin and mucous membranes;
  • Hepatitis B, C and A;
  • Viral encephalomyelitis;
  • Urethritis is not of gonococcal origin;
  • Urogenital chlamydial infection;
  • Pulmonary tuberculosis;
  • Treatment and prevention of acute respiratory diseases and influenza, parainfluenza, adviral infection.

Contraindications

In some situations, the use of Lavomax for the treatment and prevention of viral infections is prohibited. Contraindications include:

  • Individual hypersensitivity or intolerance to the main active ingredient;
  • The period of pregnancy and breastfeeding;
  • Patients under 18 years of age due to the lack of clinical experience and data on the safety of use in pediatric practice;

Since the drug contains sucrose, Lavomax tablets are contraindicated in patients with a deficiency of sucrose and isomaltose in the body.

Method of administration and dosage regimen of the drug

Tablets are prescribed to patients orally before meals. The dose of the drug depends on the indications.

For the treatment of influenza and acute respiratory viral infections, the drug should be taken as soon as possible, optimally on the day the first clinical symptoms appear. The tablet is taken once a day, and after 2 days from the start of therapy it is enough to take the medicine once every other day. The course of treatment is determined by a specialist.

To prevent influenza and viral infections during epidemic outbreaks, the patient is prescribed 1 tablet of the drug once a week for 1.5 months.

For the treatment of viral hepatitis, the drug is first taken once a day, one tablet, then every other day. The duration of treatment is determined by the doctor depending on the severity of the disease and the individual characteristics of the body.

For the treatment of chronic hepatitis B, in the first 2 days the patient is prescribed 1 tablet 2 times a day, then 1 tablet every other day. The course of treatment is at least 4 months.

As part of the complex treatment of pulmonary tuberculosis, in the first 2 days the patient is prescribed 1 tablet 2 times a day, then 1 tablet every other day. The duration of treatment is determined by a specialist individually.

Use of the product during pregnancy and lactation

The effectiveness and safety of the influence of the main active component of the drug Lavomax on the woman’s body and the intrauterine development of the fetus have not been established, therefore this drug is contraindicated while expecting a child.

It is not known whether the drug is excreted in breast milk, therefore Lavomax therapy is not recommended during lactation. If treatment is necessary, breastfeeding should be stopped so as not to harm the baby.

Adverse reactions

If the doses recommended in the instructions are followed, the drug is well tolerated by patients, however, persons with increased individual sensitivity during therapy noted the development of the following adverse reactions:

  • Increased flu-like symptoms - muscle pain, fever, lethargy, weakness, body aches;
  • Allergic skin rashes, urticaria;
  • Stomach pain, dyspeptic symptoms (diarrhea, nausea, vomiting);
  • Chills.

Overdose

Cases of overdose with Lavomax have not been described if the therapeutic dose indicated in the instructions is followed. If a large dose of the drug is accidentally administered orally, the above-described side effects may increase. In this case, treatment with the drug is canceled, and the patient is induced to vomit, after which he is allowed to take enterosorbents.

Interaction with other drugs

Lavomax is compatible with antibiotics and any other medications.

It is not recommended to drink alcohol or take medicinal tinctures containing alcohol during therapy.

special instructions

The active ingredient of the tablets does not affect the functioning of the central nervous system and does not inhibit the speed of psychomotor reactions.

The drug is not used to treat children and adolescents under 18 years of age, since the safety of the effect of the active substance on the body has not been established.

Analogs of Lavomax tablets

The following drugs are similar in their therapeutic effect to the drug Lavomax:

  • Amiksin tablets;
  • Tilarone tablets;
  • Amizon;
  • Amizon max tablets;
  • Tylaxin tablets.

Before replacing the drug with one of these analogues, you should check with your doctor about the dose and indications, since not all of the drugs listed are effective for chlamydia and other pathologies for which Lavomax is effective.

Storage and release conditions

The drug can be purchased in pharmacies freely, without a doctor's prescription. It is recommended to keep the tablets away from children in a cool place, avoiding exposure of the drug to sunlight. The expiration date of the medicine is indicated on the packaging, after which the tablets cannot be taken orally.

Lavomax price

The approximate cost of the drug Lavomax in Moscow pharmacies is 535 rubles.

Source: http://bezboleznej.ru/lavomaks